Half-year report for the six months ended 30 June 2025

更新 發佈

“H1 2025 results reflected weaker sales due to the temporary delays in third-party processing of Kyzyl concentrate. With this issue now largely addressed, we anticipate a recovery in profitability and cash flows in H2 2025. As previously disclosed, this year’s production will still be partially constrained by accumulated concentrate inventories and is expected to come below the initial guidance, with a corresponding negative impact on costs. We remain focused on meeting our revised targets and executing our strategic priorities, including the start of the full-scale construction of the Ertis POX and progressing the Syrymbet project”, said Vitaly Nesis, CEO of Solidcore Resources plc, commenting on the results.

FINANCIAL HIGHLIGHTS

The results for H1 2024 exclude those from the discontinued Russian segment of our business, which was divested in March 2024 and is categorised as a discontinued operation in the accompanying prior year financial statements.

  • In H1 2025, revenue decreased by 54% year-on-year (y-o-y), totalling US$ 325 million (H1 2024: US$ 704 million) as a deferral of the Kyzyl concentrate sales fully offset positive gold price dynamics.
  • Toll-treatment at the Amursk POX and third-party sales stabilised in July 2025, therefore the Company expects to release most of the accumulated c. 200 Koz of gold in concentrate by the year end. As a result, the Company expects revenue to be materially weighted towards H2 2025.
  • Full-year production guidance is forecasted to be 420 Koz (reduced from 470 Koz) as a part of the accumulated concentrate stockpiles will be carried forward into 2026.
  • The Company’s total cash costs (TCC)[1] were US$ 1,458/GE oz, up 52% y-o-y, reflecting the spread of costs over a smaller number of ounces sold and domestic inflationary pressures. For the full year, TCC are expected to decline to the upper edge of the US$ 1,000-1,100/GE oz guidance range as the sales ramp-up in H2 2025.
  • All-in sustaining cash costs (AISC)1 amounted to US$ 2,201/GE oz, a y-o-y increase of 72%, driven by the same factors which impacted TCC dynamics as well as an increase in sustaining CAPEX, attributable to higher capitalised stripping volumes and the renewal of the mining fleet at Komar. Full-year AISC is expected to be within the revised guidance range of US$ 1,450-1,550/GE oz, up from the original US$ 1,350-1,450/GE oz primarily due to a stronger-than-budgeted Kazakhstani tenge exchange rate in H1 2025 and lower projected sales at Kyzyl.
  • Driven by the negative revenue and costs dynamics, Adjusted EBITDA1 for the reporting period decreased by 56% y-o-y to US$ 152 million (H1 2024: US$ 346 million), with the Adjusted EBITDA margin of 47% (H1 2024: 49%).
  • Underlying net earnings1 declined to US$ 101 million (H1 2024: US$ 243 million), and net earnings[2] declined to US$ 85 million (H1 2024: US$ 238 million).
  • Capital expenditure (CAPEX) increased by 19% y-o-y to US$ 128 million[3] due to the start of the Ertis POX construction. The Company reiterates its full-year CAPEX guidance of US$ 300 million.
  • Net operating cash outflow was US$ 86 million (H1 2024: net inflow of US$ 344 million) reflecting the concentrate inventories accumulation and lower Adjusted EBITDA. The Company generated negative free cash flow1 of US$ 220 million (H1 2024: positive US$ 240 million). Free cash flow is expected to be significantly positive in the second half of the year due to the working capital release and the Company expects this will fully compensate for the negative result in H1.
  • Net cash declined to US$ 143 million as of 30 June 2025 (US$ 374 million at year-end 2024). Despite that, the liquidity position remains strong with US$ 351 million in cash on the balance sheet and US$ 139 million of undrawn credit lines. In July 2025, the Company signed a new credit facility agreement with ING for up to US$ 100 million which is expected to replace some of the maturing debt facilities.

 

OPERATING HIGHLIGHTS

  • No fatal accidents or lost time injuries were recorded among the Company’s employees and contractors during H1 2025 (consistent with 2024), reflecting our continued commitment to safety.
  • H1 GE output declined by 51% y-o-y to 123 Koz, primarily due to delays in Kyzyl concentrate processing at Amursk POX. Processing at Amursk POX resumed in late Q2 2025, with additional batches dispatched to China and a third-party smelter in Kazakhstan. With a portion of the stockpiles expected to be carried forward to 2026, full-year 2025 GE production is now forecast at 420 Koz, down from the original 470 Koz by 11%.
  • In Q2 2025, the Company continued to advance the Ertis POX project, a key initiative to strengthen operational resilience and reduce reliance on third parties for concentrate processing. On-site activities are progressing according to plan, with the main focus on the completion of foundations for the autoclave storage. The autoclave was delivered to the river port in Pavlodar and unloaded onto the shore. The transportation of the autoclave to site is expected before the year's end. The Company is undertaking an independent environmental and social impact assessment in accordance with its own corporate ESG policies and high international standards.

 

Conference call and webcast

The Company will hold a webcast on Monday, 15 September 2025, at 14:00 Astana time (10:00 London time).

To participate in the webcast, please register using the following link:

https://edge.media-server.com/mmc/p/esnhqofi

Webcast details will be sent to you via email after registration.

About Solidcore

Solidcore Resources is a leading gold producer registered in AIFC, Kazakhstan, and listed on Astana International Exchange. Solidcore operates two producing gold mines and a major growth project (Ertis POX) in Kazakhstan.

Enquiries

Investor Relations

Media

Kirill Kuznetsov

Alina Assanova

+7 7172 47 66 55 (Kazakhstan)

ir@solidcore-resources.com

Yerkin Uderbay

+7 7172 47 66 55 (Kazakhstan)

media@solidcore-resources.kz

FORWARD-LOOKING STATEMENTS

 

This release may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements speak only as at the date of this release. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “should” or similar expressions or, in each case their negative or other variations or by discussion of strategies, plans, objectives, goals, future events or intentions. These forward-looking statements all include matters that are not historical facts. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements are not guarantees of future performance. There are many factors that could cause the Company’s actual results, performance or achievements to differ materially from those expressed in such forward-looking statements. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

留言
avatar-img
留言分享你的想法!
avatar-img
EQS Newswire的沙龍
5會員
545內容數
EQS Newswire的沙龍的其他內容
2025/09/12
山東省濟南市章丘區——2025年9月 聯康生物科技集團(以下簡稱“本集團”)欣然宣佈,與擁有豐富全球商業化經驗的領先企業——科興生物製藥股份有限公司(股票代碼:688136.SH)簽署戰略合作協定。根據這一里程碑式的協議,本集團子公司北京博康健基因科技有限公司(以下簡稱“北京博康健”)授予科興
2025/09/12
山東省濟南市章丘區——2025年9月 聯康生物科技集團(以下簡稱“本集團”)欣然宣佈,與擁有豐富全球商業化經驗的領先企業——科興生物製藥股份有限公司(股票代碼:688136.SH)簽署戰略合作協定。根據這一里程碑式的協議,本集團子公司北京博康健基因科技有限公司(以下簡稱“北京博康健”)授予科興
2025/09/12
現代牙科集團與Sindan在「一帶一路」專員何力治先生見證下簽署合作備忘錄。 (2025年9月12日,香港) 全球領先之義齒器材供應商 - 現代牙科集團有限公司 (簡稱「現代牙科」或「本集團」,股份代號:03600.HK) 受邀出席由香港特區政府和香港貿易發展局合辦的第十屆「一帶一路高峰論壇」,9
Thumbnail
2025/09/12
現代牙科集團與Sindan在「一帶一路」專員何力治先生見證下簽署合作備忘錄。 (2025年9月12日,香港) 全球領先之義齒器材供應商 - 現代牙科集團有限公司 (簡稱「現代牙科」或「本集團」,股份代號:03600.HK) 受邀出席由香港特區政府和香港貿易發展局合辦的第十屆「一帶一路高峰論壇」,9
Thumbnail
2025/09/11
今年7月份,中國職業教育與藍領人才服務領軍企業優藍國際(納斯達克代碼:YOUL)正式登陸納斯達克,成為首家在美上市的中國職業教育全鏈條服務商。 面對複雜的國際資本市場環境,優藍國際憑藉獨特的“產教融合”模式和清晰的戰略路徑,為投資者提供了佈局中國藍領經濟結構性紅利的稀缺標的。 作為中國職教與藍領
2025/09/11
今年7月份,中國職業教育與藍領人才服務領軍企業優藍國際(納斯達克代碼:YOUL)正式登陸納斯達克,成為首家在美上市的中國職業教育全鏈條服務商。 面對複雜的國際資本市場環境,優藍國際憑藉獨特的“產教融合”模式和清晰的戰略路徑,為投資者提供了佈局中國藍領經濟結構性紅利的稀缺標的。 作為中國職教與藍領
看更多
你可能也想看
Thumbnail
還在煩惱平凡日常該如何增添一點小驚喜嗎?全家便利商店這次聯手超萌的馬來貘,推出黑白配色的馬來貘雪糕,不僅外觀吸睛,層次豐富的雙層口味更是讓人一口接一口!本文將帶你探索馬來貘雪糕的多種創意吃法,從簡單的豆漿燕麥碗、藍莓果昔,到大人系的奇亞籽布丁下午茶,讓可愛的馬來貘陪你度過每一餐,增添生活中的小確幸!
Thumbnail
還在煩惱平凡日常該如何增添一點小驚喜嗎?全家便利商店這次聯手超萌的馬來貘,推出黑白配色的馬來貘雪糕,不僅外觀吸睛,層次豐富的雙層口味更是讓人一口接一口!本文將帶你探索馬來貘雪糕的多種創意吃法,從簡單的豆漿燕麥碗、藍莓果昔,到大人系的奇亞籽布丁下午茶,讓可愛的馬來貘陪你度過每一餐,增添生活中的小確幸!
Thumbnail
Solidcore Resources plc (“Solidcore” or the “Company”) reports production results for the second quarter ended June 30, 2024. “In Q2, we demonstrated
Thumbnail
Solidcore Resources plc (“Solidcore” or the “Company”) reports production results for the second quarter ended June 30, 2024. “In Q2, we demonstrated
Thumbnail
今日無操作,接下來陸續公布7月營收囉。
Thumbnail
今日無操作,接下來陸續公布7月營收囉。
Thumbnail
企業今年一半的營收和獲利基本上已定下來,對於投資人來說,就是要等待8月份公布的Q2財報,到時候便可以看看企業今年上半年的獲利表現如何,但是我們還是先從月營收來一窺公司的表現如何
Thumbnail
企業今年一半的營收和獲利基本上已定下來,對於投資人來說,就是要等待8月份公布的Q2財報,到時候便可以看看企業今年上半年的獲利表現如何,但是我們還是先從月營收來一窺公司的表現如何
Thumbnail
今日​​無操作,接下來就等6月營收公布以及正式進入Q3,Q3預期是電子股的旺季,過去營收受淡季影響的在接下來應該都要有所成長。
Thumbnail
今日​​無操作,接下來就等6月營收公布以及正式進入Q3,Q3預期是電子股的旺季,過去營收受淡季影響的在接下來應該都要有所成長。
Thumbnail
Q1營收是2024年最低時期,因折舊、營業費用等因素,Q1 EPS為1.48元(本業EPS僅有0.61元,業外有0.87元)。Q1庫存進入『回補庫存』狀態,與2023.Q4相比提升20%,可視為Q2的出貨高峰期的先行指標。大戶比例從四月分開始有持續建倉(從72%上升到74%),迎合Q2的營收高峰期。
Thumbnail
Q1營收是2024年最低時期,因折舊、營業費用等因素,Q1 EPS為1.48元(本業EPS僅有0.61元,業外有0.87元)。Q1庫存進入『回補庫存』狀態,與2023.Q4相比提升20%,可視為Q2的出貨高峰期的先行指標。大戶比例從四月分開始有持續建倉(從72%上升到74%),迎合Q2的營收高峰期。
Thumbnail
此文章介紹了2023Q4的合約負債總表相關參考數據,提供投資理財參考工具,減少整理資料的時間成本。文章內容僅供參考,不能保證股價漲跌,並提醒讀者自行判斷買賣依據。
Thumbnail
此文章介紹了2023Q4的合約負債總表相關參考數據,提供投資理財參考工具,減少整理資料的時間成本。文章內容僅供參考,不能保證股價漲跌,並提醒讀者自行判斷買賣依據。
Thumbnail
此文章提供2023Q4合約負債相關參考數據,包括股本比和季增率,旨在作為投資理財參考工具,減少資料整理時間成本。內容僅供參考,不能保證股價漲跌,請自行判斷買賣依據。
Thumbnail
此文章提供2023Q4合約負債相關參考數據,包括股本比和季增率,旨在作為投資理財參考工具,減少資料整理時間成本。內容僅供參考,不能保證股價漲跌,請自行判斷買賣依據。
追蹤感興趣的內容從 Google News 追蹤更多 vocus 的最新精選內容追蹤 Google News